Do no harm: A critical risk/benefit analysis of child psychotropic medication

Journal of Family Psychotherapy

Volumn 19, Issue 1, 2008, Pages 1-19

  Sparks, Jacqueline A ^a   Duncan, Barry L ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Institute for the Study of Therapeutic Change   (United States)

Author keywords

Adolescents; Antidepressants; Attention Deficit Hyperactivity Disorder; Benefits; Children; Critical analysis; Depression; Psychostimulants; Psychotropic medication; Review; Risks

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; FLUOXETINE; METHYLPHENIDATE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; DECISION MAKING; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; FAMILY; HUMAN; HYPERKINESIA; JUVENILE; MAJOR DEPRESSION; MANIA; MEDICAL ETHICS; MOOD DISORDER; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT;

EID: 70449679039     PISSN: 08975353     EISSN: 15404080     Source Type: Journal    
DOI: 10.1080/08975350801904072     Document Type: Review

References (46)

1. Angell, M. (2000). Is academic medicine for sale? The New England Journal of Medicine, 341(20), 1516-1518.
2. Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist, 58(12), 1028-1043.
3. Birmaher, B., Brent, D. A., Kolko, D., Baugher, M., Bridge, J., Holder, D., Iyengar, S., & Ulloa, R. E. (2000). Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry, 57(1), 29-36.
4. Birmaher, B., Ryan, N. D., Williamson, D. E., Brent, D. A., & Kaufman, J. (1996). Childhood and adolescent depression: A review of the past 10 years. Part II. Journal of the American Academy of Child Psychiatry, 35(12), 1575-1583.
5. Delate, T., Gelenberg, A. J., Simmons, V. A., & Motheral, B. R. (2004). Trends in the use of antidepressants in a National sample of commercially insured pediatric patients, 1998 to 2002. Psychiatric Services, 55(4), 387-391.
6. Dooran, J. C. (2005, July 1). Pediatric panel says labels on attention-deficit drugs should get clearer cautions. Wall Street Journal, p. B.3.
7. dosReis. S., Zito, J. M., Safer, D. J., Gardner, J. F., Puccia, K. B., Owens, P. L. (2005). Multiple psychotropic medication use for youths: a two-state comparison. Journal of Child & Adolescent Psychopharmacology, 15(1), 68-77.
8. Duffy, F. F., Narrow, W. E., Rae, D. S., West, J. C., Zarin, D. A., Rubio-Stipec, M., Pincus, H. A., & Regier, D. A. (2005). Concomitant pharmacotherapy among youths treated in routine psychiatric practice. Journal of Child and Adolescent Psychopharmacology, 15(1), 12-25.
9. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., Nilsson, M., & Jacobson, J. G. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1205-1215.
10. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54(11), 1031-1037.
11. Evan, C., Siobud-Dorocant, E., & Dardennes, R. M., (2000). Critical approach to antidepressant trials: Blindness protection is necessary, feasible and measurable. The British Journal of Psychiatry, 177, 47-51.
12. Fisher, R. L., & Fisher, S. (1997). Are we justified in treating children with psychotropic drugs? In S. Fisher & R. P. Greenberg (Eds.), From placebo to panacea (pp.307-322). New York: Wiley.
13. Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under "blinder" conditions. Journal of Consulting and Clinical Psychology, 60, 664-669.
14. Greenberg, R. P., Bornstein, R. F., Zborowski, M. J., Fisher, S., & Greenberg, M. D. (1994). A meta-analysis of fluoxetine outcome in the treatment of depression. Journal of Nervous and Mental Disease, 182(10), 547-551.
15. Greenberg, R. P. & Fisher, S. (1997). Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions. In S. Fisher & R.P. Greenberg (Eds.), From Placebo to panacea: Putting psychiatric drugs to the test (pp. 115-172). New York: Wiley.
16. Greenhill, L. L., Vitiello, B., Riddle, M. A., Fisher, P., Shockey, E., March, J. S., Levine, J., Fried, J., Abikoff, H., Zito, J. M., McCracken, J. T., Findling, R. L., Robinson, J., Cooper, T. B., Davies, M., Varïpatis, E., Labellarte, M. J., Scahill, L., Walkup, J. T., Capasso, L., & Rosengarten, J. (2003). Review of safety assessment methods used in pediatric psychopharmacology. Journal of the American Academy of Child & Adolescent Psychiatry, 42(6), 627-633.
17. Harris, G. (2004, June 2). Antidepressants seen as effective for adolescents. New York Times, p. A-1.
18. Hughes, C.W., Emslie, G., Kowatch, R., Weinberg, W., Rintelmann, J., & Rush, A.J. (2000). Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology, 23(5), 591-594.
19. Integrity in Science: A CSPI Project. http://www.cspinet.org/integrity/.
20. Jureidini, J. N., Doecke, C. J., Mansfield, P. R., Haby, M. M., Menkes, D. B., & Tonkin, A. I. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal, 328, 879-883.
21. Kazdin, A. E. (2003). Psychotherapy for children and adolescents. Annual Review of Psychology, 54, 253-276.
22. Lenzer, J. (2004a). Specialists challenge claim that fluoxetine plus talk therapy works best for depressed adolescents. British Medical Journal, 329, September 4. Retrieved October 7, 2004, from http://www.bmj.com.
23. Martin, A., & Leslie, D. (2003). Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured youths, 1997-2000. The American Journal of Psychiatry, 160(4), 757-764.
24. Martin, A., Van Hoof, T., Stubbe, D., Sherwin, T., & Scahill, L. (2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services, 45(1), 72-77.
25. McKenzie, J. (2004, June 2). Promises of Prozac. ABCNEWS.com. Retrieved June 3, 2004, from http://w.w.w.abcnews.go.com/sections/WNT/MedicinecuttingEdge/ teens-prozac- 40602. html.
26. Medco Health Solutions, Inc. (2004, May 18). Medco study reveals pediatric spending spike on drugs to treat behavioral problems. Retrieved May 24, 2004, from http:// www.drugtrend.com/medco/consumer/drugtrend/trends.
27. Michael, K. D., & Crowley, S. L. (2002). How effective are treatments for child and adolescent depression? A meta-analytic review. Clinical Psychology Review, 22(2), 247-269.
28. Moncrieff, J., Wessely, S., Hardy, R. (2004). Active placebo versus antidepressants for depression. The Cochrane Database of Systematic Review: The Cochrane Library, 2, Oxford: Update Software.
29. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56 (12), 1073-1086.
30. MTA Cooperative Group. (2004a) 24-month outcomes of treatment strategies for attention deficit/hyperactivity disorder (ADHD): The NIMH MTA follow-up. Pediatrics, 113, April, 754-761.
31. MTA Cooperative Group (2004b). Changes in effectiveness and growth during the follow-up phase of the multimodal treatment study of children with attention deficit/ hyperactivity disorder. Pediatrics, 113, April, 762-769.
32. Nock, M. K. (2003). Progress review of the psychosocial treatment of child conduct problems. Clinical Psychology: Science and Practice, 10(1), 1.
33. Olfson, M., Marcus, S. C., Weissman, M. M., & Jensen, P. S. (2002). National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry, 41(5), 514-521.
34. Pelham, W. (1999). The NIMH multimodal treatment study for attention-deficit hyperactivity disorder: just say yes to drugs alone. Canadian Journal of Psychiatry, 44, 981-990.
35. Raghavan, R., Zima, B. T., Andersen, R. M., Leibowitz, A. A., Schuster, M. A., & Landsverk, J. (2005). Psychotropic medication use in a national probability sample of children in the child welfare system. Journal of Child and Adolescent Psychopharmacology, 15(1), 97-106.
36. Rigoni, G. (2004, February 2). Drug utilization for selected antidepressants among children and adolescents in the U.S. In Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee. Retrieved on June 2, 2004 from http://www.fda.gov/ohrms/dockets/ac/ 04/slides/4006s1.htm.
37. Treatment for Adolescents with Depression Study (TADS) Team (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA, 292(7), 807-820.
38. U.S. Food and Drug Administration (2001, June 25). Medical review. Retrieved July 3, 2004 from http://www.fda.gov/dcer/foi/nda/2003/18936SO64- Prozac%Pulvules-medr.pdf.
39. U.S. Food and Drug Administration (2003, January 3). FDA approves Prozac for pediatric use to treat depression and OCD. Retrieved January 25, 2003 from http:// *www.fda.gov/bbs/topics/ANSWERS/2003/ANS01187.html.
40. U.S. Food and Drug Administration (2004, October 15). FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Retrieved October 30, 2004 from http://www.fda.gov/ bbs/topics/news/2004/ NEW01124.html.
41. Wilens, T. E., Biederman, J., Kwon, A., Chase, R., Greenberg, L., Mick, E., & Spencer, T. J. (2003). A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with serotonin reuptake inhibitors. Journal of Child & Adolescent Psychopharmacology, 13(2), 143-152.
42. Willman, D. (2003, December 7). Stealth merger: Drug companies and government medical research. Los Angeles Times, p. A.1.
43. Willman, D. (2005, July 14). NIH inquiry shows widespread ethical lapses, lawmaker says. Los Angeles Times, p. A.23.
44. Zito, J. M., & Safer, S. J. (2005). Recent child pharmacoepidemiological findings. Journal of Child and Adolescent Psychopharmacology, 15(1), 5-9.
45. Zito, J. M., Safer, S. J., DosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. JAMA, 283(8), 1025-1030.
46. Zito, J. M., Safer, S. J., DosReis, S., Gardner, J. F., Magder, L., Soeken, K., Boles, M., Lynch, F., & Riddle, M. A. (2003). Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatric & Adolescent Medicine, 157(1), 17-25.